Hemagglutinin (A/Michigan/45/2015) (H1N1)-pdm09-Like
|
Catalog Number:
IA-H1-M15WP
|
Price: Starting at $189.00
Detailed Description
|
IA-H1-M15WP
|
|
Name
|
Hemagglutinin (aa 18-529)(A/Michigan/45/2015)(H1N1)-pdm09-like
|
|
Description
|
6x His tagged (C-terminal) full-length hemagglutinin HA (A/Michigan/45/2015/H1N1) (amino acid 18-529) (GenBank Accession No. APC60198.1) (recommended FLU vaccine virus strain by WHO and FDA for the 2017-2018 & 2018-2019 seasons in North America)
|
|
Source
|
Glycosylated recombinant full-length HA protein expressed in HEK293 cells
|
|
Application
|
Western Blot, ELISA, HI, immunogen, etc.
|
|
Purity
|
>95% (SDS-PAGE)
|
|
Endotoxin
|
<0.01 EU per µg of purified protein by LAL test
|
|
Size
|
50 µg, 1mg
|
|
For Downloading
|
==>> DATA SHEET ==>> SDS
|
About Influenza A Virus Hemagglutinin (HA) Recombinant Protein (A/Michigan/45/2015, H1N1pdm09)
Influenza A virus is an enveloped, negative-sense segmented RNA virus belonging to the family Orthomyxoviridae. Hemagglutinin (HA) is the major viral surface glycoprotein responsible for viral attachment to sialic acid-containing receptors on host cells and initiation of membrane fusion during viral entry. As the principal surface antigen, HA is the primary target of neutralizing antibodies and seasonal influenza vaccines. The A/Michigan/45/2015 (H1N1)pdm09 strain was selected by the World Health Organization (WHO) as the H1N1 vaccine component for the 2017–2018 and 2018–2019 Northern Hemisphere influenza seasons, making it an important reference strain for influenza surveillance, vaccine development, and immunological research.
eEnzyme's Influenza A/H1N1pdm09 Hemagglutinin (HA) Recombinant Protein (A/Michigan/45/2015) is produced for research use and is suitable for antibody screening, receptor-binding studies, ELISA development, Western blotting, epitope mapping, structural characterization, and influenza vaccine research. This recombinant protein provides a valuable reagent for investigating influenza virus biology, host immune responses, and antiviral therapeutic development.
Applications
• Influenza H1N1 HA research
• Neutralizing antibody screening
• Receptor-binding studies
• ELISA and Western blot assays
• Epitope mapping
• Structural biology studies
• Influenza vaccine research
• Antiviral therapeutic development
Biological Significance of Influenza Hemagglutinin
Influenza HA is the functional viral attachment and fusion protein that initiates infection by recognizing sialic acid receptors on susceptible host cells. As the dominant antigen recognized by protective antibodies, HA remains the primary target for seasonal influenza vaccines and therapeutic antibody development. The Influenza A/H1N1pdm09 Hemagglutinin (HA) Recombinant Protein (A/Michigan/45/2015) provides a valuable research tool for studies of influenza virus pathogenesis, immune responses, vaccine evaluation, and diagnostic assay development.
Selected Recent Citations:
1. Long-Term Recovery of the Adaptive Immune System in Rhesus Macaques After Total Body Irradiation. Advances in Radiation Oncology, April 2021.
2. A facile technology for the high-throughput sequencing of the paired VH: VL and TCRβ: TCRα repertoires. Sci. Adv. 6, eaay9093 (2020).
|
|
|